retatrutide phase 2 trial type 2 diabetes weight loss 2024 VisualAbstract: reduces body by 17.5% in patients with obesity Transforming obesity: The advancement of

The company temporarily paused advertising for the program because of shortages last year, and it offered refunds and credits to patients who weren't able to pick up their medication within 30 days of getting a prescription

All research compounds, including retatrutide, must be used strictly in controlled laboratory settings by qualified research professionals

If you want a broader explanation of this drug family, the GLP-1 Explained article gives useful context on how incretin medicines fit into diabetes and weight management care

For perspective on where this lands against the field (placebo-adjusted weight loss): Type 2 diabetes TRANSCEND-T2D-1 (n = 537, 40 weeks) Published simultaneously in The Lancet

Aside from the evidence-backed results people achieve with Sofwave, the treatment is also quick, non-invasive, and provides gradual, long-lasting results

Potential Impact: If 2.4mg/2.4mg achieves 20.4% weight loss, could 2.4mg/7.2mg achieve 25-27%